Julio Delgado
www.mendeley.com
0000-0002-5157-4376
Hospital Clínic de Barcelona
16 papers found
Refreshing results…
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients
A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma
Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
Missing publications? Search for publications with a matching author name.